SAMUEL LYNCH, DMD, DMSC
MEMBER, BOARD OF DIRECTORS, VANDERBILT UNIVERSITY MEDICAL CENTER
FOUNDER, CEO AND CHAIRMAN, LYNCH BIOLOGICS, LLC
Dr. Lynch is an accomplished CEO, translational scientist, and entrepreneur. He graduated from the dual degree program at Harvard Medical and Dental Schools with a DMSc and specialty certification in periodontology, respectively, in 1989, and served as a member of the faculty until 1995 at which time he transitioned into the industry. He has founded and led several medical device and biotechnology companies, and invented and/or played a key role in the development of many of the leading regenerative brands in dentistry including BioOss®, BioGide® and GEM 21S®, as well as in orthopedics including Augment® Bone Graft and Augment Injectable® Bone Graft. He was also the founder and CEO of BioMimetic Therapeutics which he grew into a publicly-traded company on Nasdaq [BMTI], and sold in 2013 for approximately $400 million.
He currently serves on the governing Board of Directors of Vanderbilt University Medical Center, a top 10-15 medical center in the United States with approximately 28,000 employees and $6 billion in annual revenues, where has chaired both the Audit & Compliance Committee and the Compensation & Leadership Development Committee. He is currently the CEO and Chairman of Lynch Biologics, LLC, serves on several Boards of private biotechnology companies, and is the Chairman of the BioTN Foundation, a nonprofit foundation he and his wife Leslie started in 2007 to promote k-12 STEM education. He is the author of >250 publications and patents, mostly in the regenerative dentistry and medicine fields, as well as the editor of two books on tissue engineering.